{
    "clinical_study": {
        "@rank": "80627", 
        "acronym": "YH4808-108", 
        "arm_group": [
            {
                "arm_group_label": "YH4808, amoxicillin, clarithromycin", 
                "arm_group_type": "Experimental", 
                "description": "single administration of YH4808 or amoxicillin or clarithromycin or YH4808 + amoxicillin + clarithromycin"
            }, 
            {
                "arm_group_label": "YH4808, amoxicillin and clarithromycin", 
                "arm_group_type": "Experimental", 
                "description": "7 days repeat administration of YH4808, amoxicillin and clarithromycin for H.pylori eradication"
            }, 
            {
                "arm_group_label": "YH4808 and amoxicillin", 
                "arm_group_type": "Experimental", 
                "description": "7 days repeat administration of YH4808 and amoxicillin for H.pylori eradication"
            }, 
            {
                "arm_group_label": "nexium, amoxicillin and clarithromycin", 
                "arm_group_type": "Active Comparator", 
                "description": "BID, 7 days repeat administration of nexium, amoxicillin and clarithromycin for H.pylori eradication"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is not only to explore pharmacokinetic interaction  after single\n      oral administration but also pharmacodynamics interaction  after multiple oral\n      administration of YH4808, amoxicillin and clarithromycin each separately versus\n      coadministration of YH4808, amoxicillin and clarithromycin in healthy volunteers"
        }, 
        "brief_title": "The PK and PD Interaction Between YH4808, Amoxicillin and Clarithromycin in Healthy Subjects", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. healthy male age 20 to 55 over 55kg with Ideal body weight(BMI:18.5~25)\n\n          2. Subject who has no congenital, chronic disease and disease symptoms in medical\n             examination result\n\n          3. Subject who is judged to be eligible by principal investigator or sub-investigator\n             according to various reasons including their abnormal test results(clinical\n             laboratory test, 12-lead GCG etc)\n\n        Exclusion Criteria:\n\n          1. Subject who is hypersensitive to components contained in YH4808 or this drug\n\n          2. Subject who has history or presence of clinically significant diseases in liver,\n             kidney, gastrointestinal tract, nervous system, respiratory system, endocrine system,\n             blood tumor, cardiovascular, urinary system, and mental disorder\n\n          3. Subject who has history of surgical operation or diseases related to gastrointestinal\n             symptom (e.g. Crohn's disease, ulcer etc except appendectomy or simple for hernia)\n\n          4. Other exclusions apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "95", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01921647", 
            "org_study_id": "YH4808-108"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "YH4808, amoxicillin, clarithromycin", 
                    "YH4808, amoxicillin and clarithromycin", 
                    "YH4808 and amoxicillin"
                ], 
                "intervention_name": "YH4808", 
                "intervention_type": "Drug", 
                "other_name": "experimental drug"
            }, 
            {
                "arm_group_label": "nexium, amoxicillin and clarithromycin", 
                "intervention_name": "Nexium", 
                "intervention_type": "Drug", 
                "other_name": "active comparator"
            }, 
            {
                "arm_group_label": [
                    "YH4808, amoxicillin, clarithromycin", 
                    "YH4808, amoxicillin and clarithromycin", 
                    "YH4808 and amoxicillin", 
                    "nexium, amoxicillin and clarithromycin"
                ], 
                "intervention_name": "Amoxicillin", 
                "intervention_type": "Drug", 
                "other_name": "experimental drug"
            }, 
            {
                "arm_group_label": [
                    "YH4808, amoxicillin, clarithromycin", 
                    "YH4808, amoxicillin and clarithromycin", 
                    "nexium, amoxicillin and clarithromycin"
                ], 
                "intervention_name": "clarithromycin", 
                "intervention_type": "Drug", 
                "other_name": "experimental drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amoxicillin", 
                "Clarithromycin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "safety/tolerability and pharmacokinetics/pharmacodynamics", 
        "lastchanged_date": "December 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Yonsei University Severance Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "The Exploration for Pharmacodynamics and Pharmacokinetic Interaction Between YH4808, Amoxicillin and Clarithromycin in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Yonsei University Severance Hospital", 
            "last_name": "Min soo Park, Ph.D, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Cmax, AUClast of YH4808, M3, amoxicillin, clarithromycin, 14-hydroxyclarithromycin", 
            "safety_issue": "No", 
            "time_frame": "pre dose, 16 times after dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01921647"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Cmax, AUClast of M8, AUCinf, t1/2, Tmax of YH4808, M3, M8, amoxicillin, clarithromycin, 14-hydroxyclarithromycin", 
            "safety_issue": "No", 
            "time_frame": "pre dose, 16 times after dosing"
        }, 
        "source": "Yuhan Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yuhan Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}